COEP Stock Price, Coeptis Therapeutics Holdings, . Quote, Chart

Market Summary

USD0.38+0.01

Delayedas of 03 May 2024, 12:07 pm

2.70%

COEP Stock Price

View Fullscreen

COEP RSI Chart

COEP Valuation

Market Cap

8.2M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

109.29

EV/EBITDA

-0.08

Price/Free Cashflow

-2.53

COEP Price/Sales (Trailing)

COEP Profitability

Free Cashflow Yield

-39.49%

COEP Fundamentals

COEP Revenue

COEP Earnings

Breaking Down COEP Revenue

52 Week Range

0.41

(Low)(High)

Last 7 days

12.5%

Last 30 days

16.1%

Last 90 days

-35.7%

How does COEP drawdown profile look like?

COEP Financial Health

COEP Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	97.2K	87.3K	1.1M	75.0K
2020	0	0	0	37.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Coeptis Therapeutics Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 12, 2024	desilva tara	bought	1,304	0.575887	2,266	-
Jan 10, 2024	cogley brian	bought	3,350	0.67	5,000	chief financial officer
Jan 08, 2024	mehalick david	bought	13,262	0.662999	20,004	ceo and president
Jan 05, 2024	salkind gene	bought	8,004	0.69	11,600	-
Jan 05, 2024	mehalick david	bought	3,484	0.69	5,050	ceo and president
Jan 05, 2024	yerace daniel alexander	bought	7,486	0.69	10,850	vp of operations
Jan 05, 2024	cochran christopher p.	bought	5,390	0.77	7,000	-
Dec 07, 2023	mehalick david	gifted	-	-	-700,000	ceo and president
Aug 29, 2023	salkind gene	bought	4,046	1.01	4,006	-
Aug 25, 2023	salkind gene	bought	26,060	0.91	28,638	-

Which funds bought or sold COEP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	unchanged	-	-27,000	17,000	-%
Apr 22, 2024	Arista Wealth Management, LLC	new	-	14,077	14,077	0.01%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-25.00	-	-	-%
Apr 17, 2024	ACT Advisors, LLC.	new	-	3,112	3,112	-%
Mar 11, 2024	VANGUARD GROUP INC	added	21.3	-18,745	85,217	-%
Feb 26, 2024	Virtu Financial LLC	new	-	12,000	12,000	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%
Feb 15, 2024	SkyView Investment Advisors, LLC	unchanged	-	1,000	2,000	-%

Are Funds Buying or Selling COEP?

Are funds buying COEP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own COEP

No. of Funds

Peers (Alternatives to Coeptis Therapeutics Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Coeptis Therapeutics Holdings, Inc. News

Latest updates

Coeptis Therapeutics Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q3	2020Q2	2020Q1
Revenue	-100.0%	-	1,000,000	-	75,000	9,753	2,520	9,888	8,600	16,365	4,508
Cost Of Revenue	-	-	-	-	-	960,856	-	1,492	-	1,869	-
Gross Profit	-	-	-	-	75,000	-960,856	-	8,396	-	14,496	4,508
Operating Expenses	-57.4%	2,961,018	6,947,898	2,624,069	1,775,081	3,810,974	487,366	1,617,492	12,115	701,740	400,907
S&GA Expenses	-	-	-	-	2,918	-1,436	4,513	-	3,515	-	-
R&D Expenses	-	-	-	-	-	-	-	-	-	3,543	-
EBITDA Margin	-1166.6%	-170	-13.49	-123	-90.01	-282	-	-	-	-	-
Interest Expenses	-142.0%	-79,255	188,559	43,098	34,737	148,192	-	183,871	-36,341	36,341	34,500
Income Taxes	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	52.2%	-2,839,608	-5,946,356	-2,713,235	-1,950,081	-4,761,014	-	-1,820,647	-	-685,254	-1,896,399
EBT Margin	-1165.5%	-179	-14.17	-128	-94.86	-297	-	-	-	-	-
Net Income	52.2%	-2,839,608	-5,946,356	-2,713,235	-1,950,081	-6,832,652	-489,239	-1,820,647	-13,748	-685,254	-1,896,399
Net Income Margin	-1015.2%	-179	-16.08	-137	-114	-297	-80.51	-64.26	-	-	-
Free Cashflow	94.3%	-208,879	-3,650,146	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet												(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q1	2019Q4
Assets	72.7%	11,265	6,524	6,749	6,766	7,683	2,738	2,122	300	203	106	9.00	20.00
Current Assets	210.3%	7,379	2,378	2,344	2,180	2,836	1,933	2,057	225	-	-	-	-
Cash Equivalents	209.9%	7,371	2,378	2,344	2,180	2,810	1,911	2,035	203	5.00	2.00	9.00	440
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-2.6%	13.00	13.00	14.00	14.00	14.00	15.00	15.00	16.00	-	-	-	-
Liabilities	1.3%	4,521	4,463	4,412	4,415	7,110	4,879	-	5,444	3,637	1,830	23.00	20.00
Current Liabilities	1.4%	4,315	4,256	2,705	2,765	5,445	4,714	5,671	5,279	50.00	38.00	23.00	20.00
Long Term Debt	0%	150	150	1,650	1,650	1,650	150	150	150	-	-	-	-
LT Debt, Non Current	0%	150	150	1,650	1,650	1,650	150	150	150	-	-	-	-
Shareholder's Equity	227.2%	6,743	2,061	2,337	2,351	573	-	-	-	-	-	-	919
Retained Earnings	-10.0%	-62,181	-56,532	-46,729	-27,550	-24,710	-18,764	-16,050	-14,100	-526	-36.85	-13.40	-150*
Additional Paid-In Capital	17.6%	68,921	58,587	49,061	30,144	23,903	16,538	11,863	8,955	482	-159*	-159*	-159*
Accumulated Depreciation	2.9%	12.00	12.00	12.00	11.00	11.00	11.00	10.00	10.00	-	-	-	-
Shares Outstanding	10.8%	43,207	39,013	38,429	36,754	34,751	29,544	29,975	26,768	1,659	1,589	1,589	1,589

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q3	2020Q2	2020Q1	2019Q4	2019Q4	2019Q3
Cashflow From Operations	0.0%	-1,033	-1,033	-961	-208	-3,650	25.00	-655	-3,110	-	-2,528	-	-47.15	-1,590	-	99*	-99*
Share Based Compensation	-	-	-	-	-	-	-	-	-480	479	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	3,054	-4,054	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	464.2%	6,026	1,068	1,126	-3,475	8,603	602	2,487	2,877	-	2,567	-	78.00	1,500	20.00	-99*	99*

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

CEO	Mr. David Mehalick
WEBSITE	https://coeptistx.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Coeptis Therapeutics Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Coeptis Therapeutics Holdings, Inc.? What does COEP stand for in stocks?

COEP is the stock ticker symbol of Coeptis Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Coeptis Therapeutics Holdings, Inc. (COEP)?

As of Thu May 02 2024, market cap of Coeptis Therapeutics Holdings, Inc. is 8.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COEP stock?

You can check COEP's fair value in chart for subscribers.

What is the fair value of COEP stock?

You can check COEP's fair value in chart for subscribers. The fair value of Coeptis Therapeutics Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Coeptis Therapeutics Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COEP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Coeptis Therapeutics Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether COEP is over valued or under valued. Whether Coeptis Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Coeptis Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COEP.

What is Coeptis Therapeutics Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, COEP's PE ratio (Price to Earnings) is -0.22 and Price to Sales (PS) ratio is 109.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COEP PE ratio will change depending on the future growth rate expectations of investors.